# Aptevo Reports 87% Clinical Benefit and 81% Remission in 31 Evaluable Frontline AML Patients Through Cohort 5, Substantially Outperforming Benchmark; RAINIER on Track for 2026 Completion and Phase 2 Dose Selection
Canonical URL: https://biopharmsignal.com/news/APVO/aptevo-reports-87-clinical-benefit-and-81-remission-in-31-evaluable-frontline-aml-patients-through-cohort-5-substantially-outperforming-benchmark-rainier-on-track-for-2026-completion-and-phase-2-dose-selection
Ticker: APVO
Company: Aptevo Therapeutics
Source: Aptevo Therapeutics
Published: 2026-05-06 12:05 EST
Original Source URL: https://aptevotherapeutics.gcs-web.com
## Summary

Program Enters Final Stage of Dose Optimization Data Continue to Demonstrate Strong Clinical Activity and Favorable Safety Across an Expanding Frontline Dataset SEATTLE, WA / ACCESS Newswire / May 6, 2026 / Aptevo Therapeutics Inc. (Nasdaq:APVO) today reported new clinical results from its RAINIER

## Article Body
Program Enters Final Stage of Dose Optimization Data Continue to Demonstrate Strong Clinical Activity and Favorable Safety Across an Expanding Frontline Dataset SEATTLE, WA / ACCESS Newswire / May 6, 2026 / Aptevo Therapeutics Inc. (Nasdaq:APVO) today reported new clinical results from its RAINIER
## Recent Company News
- 2026-05-28 12:05 EST — [Aptevo Therapeutics Appoints Mary J. Janatpour, Ph.D., as Senior Vice President & Chief Scientific Officer](https://biopharmsignal.com/news/APVO/aptevo-therapeutics-appoints-mary-j-janatpour-ph-d-as-senior-vice-president-and-chief-scientific-officer) — Source: Aptevo Therapeutics
- 2026-05-27 12:05 EST — [Aptevo and Niowave Launch Strategic Collaboration for Radiopharmaceutical Therapeutic Development, Includes Strategic Equity Investment by Niowave at Closing](https://biopharmsignal.com/news/APVO/aptevo-and-niowave-launch-strategic-collaboration-for-radiopharmaceutical-therapeutic-development-includes-strategic-equity-investment-by-niowave-at-closing) — Source: Aptevo Therapeutics
- 2026-05-13 12:05 EST — [Aptevo Therapeutics Provides a 1Q26 Business Update; RAINIER on Track for 2026 Completion and Phase 2 Dose Selection](https://biopharmsignal.com/news/APVO/aptevo-therapeutics-provides-a-1q26-business-update-rainier-on-track-for-2026-completion-and-phase-2-dose-selection) — Source: Aptevo Therapeutics
- 2026-05-06 12:05 EST — [Aptevo Reports 87% Clinical Benefit and 81% Remission in 31 Evaluable Frontline AML Patients Through Cohort 5, Substantially Outperforming Benchmark; RAINIER on Track for 2026 Completion and Phase 2 Dose Selection](https://biopharmsignal.com/news/APVO/aptevo-reports-87-clinical-benefit-and-81-remission-in-31-evaluable-frontline-aml-patients-through-cohort-5-substantially-outperforming-benchmark-rainier-on-track-for-2026-completion-and-phase-2-dose-selection) — Source: Aptevo Therapeutics
- 2026-03-26 12:05 EST — [Aptevo Provides State of the Business Report and 2025 Financial Results](https://biopharmsignal.com/news/APVO/aptevo-provides-state-of-the-business-report-and-2025-financial-results) — Source: Aptevo Therapeutics
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)